# Glenzocimab for REperfusion in the Setting of Endovascular Therapy for Brain infarctioN: GREEN Study

> **NCT05559398** · PHASE2,PHASE3 · NOT_YET_RECRUITING · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 260 (estimated)

## Conditions studied

- Stroke, Acute
- Stroke, Ischemic

## Interventions

- **DRUG:** Glenzocimab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05559398
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2022-10-10
- **Primary completion:** 2025-10-10
- **Final completion:** 2026-10-10
- **Target enrollment:** 260 (ESTIMATED)
- **Last updated:** 2022-09-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05559398

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05559398, "Glenzocimab for REperfusion in the Setting of Endovascular Therapy for Brain infarctioN: GREEN Study". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05559398. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*